NanoBio Corporation Announces Publication of Study Results For Intranasal Nanoemulsion-Adjuvanted Vaccine
7/21/2011 7:18:15 AM
ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio® Corporation announced today that data from its ferret influenza vaccine study of NB-1008 have been published in the July 2011 issue of Clinical Vaccine Immunology by the American Society of Microbiology. Data generated from the study demonstrate the robust antigen-sparing properties of NB-1008 and provided the necessary validation to move immediately into human studies. A Phase 1a study of NB-1008 was subsequently completed in 2010, showing NB-1008 was well-tolerated while inducing both mucosal and systemic immunity following intranasal vaccination.
comments powered by